|Bid||20.86 x 4000|
|Ask||21.35 x 3000|
|Day's Range||20.60 - 21.39|
|52 Week Range||16.63 - 39.12|
|Beta (3Y Monthly)||2.05|
|PE Ratio (TTM)||344.26|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.57|
J.P. Morgan’s Chris Schott told a look at what he calls New Pfizer, the biopharma business that will be left after the spinoff of the unit that makes drugs such as Viagra and Lipitor.
[Editor's note: This story was previously published in February 2019. It has since been updated and republished.]Overall, the stock market continued its huge improvement throughout 2019, compared to where it ended in 2018; it has been a complete turnaround from last year's drop, when stocks entered bear-market territory. Markets started slipping again in the month of August, traded in a range, and then turned to rally to new all-time highs.But even though many stocks have completely erased all of their losses and made it back into the green, not all stocks have done so well. What this means is that while there are still plenty of duds out there, there are also a few undervalued stocks to buy; it has just become a little trickier to find them amid all the flashy comeback stories.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTo find the best stocks to buy now, disciplined investors might start with their own watch list, which should contain "wish list" stocks that are usually too expensive or have been put there to be on the back burner for later. Among such stocks, companies that got left out of the rally are the most compelling. Even better, some of the best undervalued stocks to buy are those that dropped by double-digit percentages during the current rally.Why is that?Stocks that have already priced in current and possible negative news typically lower the risk for investors. Such companies may work to resolve the business problem at hand, which improves its prospects and leads to a higher share price in the long run. As long as the bad news reported is a temporary setback and the business model is not broken, the risks behind buying a stock on a dip are lower. * 8 Dividend Stocks to Buy for a Recession With all of that in mind, here are five undervalued stocks to buy that aren't as scary as they seem. Sony (SNE)Investors who held Sony (NYSE:SNE) stock through the Q2 2019 earnings report posted on July 30 enjoyed the rally that followed. The stock rose from $54.50 to nearly $60 recently. The company reported revenue falling just 1.4% year-over-year but operating income rose 18%, up 35.9 billion yen (US $332.2 million).Now that Sony is trading at yearly highs, investors need not sell the stock just yet.Why not?In a Sept 13 report, video game sales in August fell again by 18%, to $666 million. The industry could not count on any big game title hits to lift monthly sales. But the gaming sector has some hope ahead. When Sony's Playstation 5 arrives, SNE will have more power than ever. Though the PS5 release will release no sooner than mid-2020, 8K support and game refreshes should give Sony another boost in revenue when the time comes.Sony faced a few headwinds in the quarter. Contributions from first-party software titles fell. Sales of non-first party titles declined. But PS4 hardware sales rose, as did network service sales, including sales of PlayStation Plus. Celestica (CLS)In July, Celestica (NYSE:CLS) reported weak Q2/2019 results that sent the stock to as low as $6 by the end of August. Celestica reported revenue of $1.45 billion, down 15% from last year. Its aerospace and defense segment etched out a 2% revenue growth in the period, offset by a 23% decline in revenue from its Connectivity and Cloud Solutions (CCS) division. Adjusted EPS was $0.12, down from $0.29 last year. In September, the stock staged a major rally.The company supplies equipment in ATS -- aerospace and defense, industrial, smart energy, health tech and capital equipment. Its enterprise unit consists of servers and storage. Why then, should investors believe the company will offset the weakness it faces in the eroding semiconductor market?Celestica is cutting costs in operations to align the business with the lower revenue. It will continue to build its capital equipment business. Management believes the fundamentals in this space will only improve in the long run. As next-generation adoption in display continues, its OLED business, for example, will add to its bottom line.Celestica stock is still an undervalued play worth considering. The stock may underperform a while longer and risks disappointing investors. Again. Consider watching the stock's next earnings report before committing to a position. * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars Celestica stock is an undervalued stock worth considering. AbbVie (ABBV)Back when I first wrote this list of undervalued stocks, Allergan (NYSE:AGN) was the pick in this slot. And it paid off. Investors buying Allergan at the start of 2019 may have made up to $50 a share, peak to trough. In June, the stock fell below $115, only to peak at around $165 in July when my new pick, AbbVie (NYSE:ABBV), agreed to buy out the firm for $63 billion. AbbVie's rationale for acquiring Allergan is two-fold.First, it views Allergan's portfolio of products, including Botox, as attractive. Second, it has the time to use the strong cash flow from Humana to pay off its Allergan acquisition. Once Humana faces fierce competition from generics, AbbVie will have paid off much of the debt related to the AGN buyout. And in a few years time, Allergan's drugs in the development pipeline will be ready for market.AbbVie's long-term future planning through the AGN acquisition makes AbbVie stock appealing for dividend-income investors. Even though shares rose from a $62.66 52-week low to $71.55, the stock still pays a dividend that yields 6%.At a Sep. 10 Healthcare Conference, AbbVie reiterated its commitment to cut debt and to continue growing its dividend. It will also allocate some cash for smaller mid- to late-state pipeline opportunities. Management has a good handle on integrating Allergan into its business but it will not let its existing pipeline suffer in any way.ABBV trades at an ~10% discount to the analyst price target of $79, but I think the AGN acquisition brings ABBV far more upside than that. Innoviva (INVA)Innoviva (NASDAQ:INVA) is another stock in the drug space whose large drop starting in late January continued throughout 2019. The stock may not yet be done falling. Why not?The fell began when the FDA approved Mylan's (NASDAQ:MYL) generic version of Advair, which GlaxoSmithKline (NYSE:GSK) produces. This forced investors to worry about Innoviva's prospects because the company is paid royalties from Glaxo. In the third quarter, Innova received $65.1 million in royalty revenues from Glaxo.Investors appear to be overreacting to the generic competition. If demand for Innoviva's formulation does not drop and prices hold, royalty revenues should not fall as much as markets think, which makes INVA an ideal undervalued stock to buy now.Innoviva shares trended lower throughout 2019, as the stock lost $3 on its stock price by late-July. Investors sold the stock following the company's weak Q2 report. Innoviva reported Glaxo (NYSE:GSK) royalties falling 18% to $313.9 million. Overall, there was a net income decline of 31% (an EPS of $0.34).In its press release, the company said:"Management and the board continue to examine potential strategic actions to maximize future shareholder value." * 7 Momentum Stocks to Buy On the Dip Innoviva incurred expenses related to the evaluation of strategic options. But it will need to deliver on better shareholder value to attract stock buyers. Vodafone (VOD)Telecom stocks were out of favor heading into 2019. Now, telecom stocks are no longer out of favor. But Vodafone (NASDAQ:VOD), which after cratering in May, has just barely climbed back to it's pre-Christmas levels. So VOD is definitely still an undervalued stock.On July 26, Vodafone reported revenue stabilizing, falling just 2.3% Y/Y. The results sent VOD stock up 9% on the day. And ever since the stock bottomed at $16, it continues to run higher, closing recently at close to $20. In the fiscal Q1 2020 report, Vodafone said it enjoyed record low mobile contract churn. The deepening customer engagement will only strengthen as the telecom company launches 5G in all major EU markets.Service revenue in Q1 was mostly flat, down 0.2% and 0.5 pp sequentially.Simplifying the mobile plan offering will likely lead to higher revenue growth ahead. For example, Vodafone migrated 500,000 SIMs to a new unlimited offer. This will also increase ARPU and keep customers from switching to competitor services.Vodafone shares pay a dividend yield of 5.2%. If Vodafone grows its U.K. business as it signs on users to its 5G services and cuts costs as it signs on more customers, VOD stock will finally move higher.As of this writing, Chris Lau owned shares of Innoviva and AbbVie.The post 5 Undervalued Stocks to Buy appeared first on InvestorPlace.
HERTFORDSHIRE, England and PITTSBURGH, Sept. 17, 2019 /PRNewswire/ -- Mylan N.V. (MYL) today announced the U.S. launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, a generic version of AstraZeneca's Faslodex® Injection. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is used to treat certain types of advanced breast cancer in women who have experienced menopause as monotherapy and in advanced or metastatic breast cancer in combination with other products. "Mylan's launch of Fulvestrant Injection represents an important addition to our growing oncology portfolio and, more importantly, expands the available treatment options for women who are facing advanced or metastatic stages of breast cancer," said Mylan President Rajiv Malik.
Pfizer (PFE) sales in the second half may take a hit due to business development activity, incremental currency headwinds and potentially lower sales of key drugs Prevnar and Xeljanz.
Pfizer stock has tumbled, below other pharmaceutical stocks. Recent news has been upbeat with a drug approval and acquisitions. But the question remains: Is Pfizer stock a buy right now?
Results for Glatiramer Acetate (GA) Depot 3 year analysis in RRMS, GA Depot safety results in RRMS and PPMS, and novel anti-BMP for remyelination will be presented ECTRIMS 2019.
Acorda's (ACOR) lead MS drug Ampyra is hit by generic rivalry in the United States, which is hurting the company's top line. Parkinson's disease drug Inbrija can be an ideal replacement.
For the first time in over a week, the market moved the same direction two days in a row. The S&P 500 made a 1.27% gain on Thursday, though that still leaves it below the key 50-day moving average line. The volume behind the advance wasn't exactly thrilling either.Source: Shutterstock Computer company Dell Technologies (NYSE:DELL) took the lead, gaining more than 3% during the regular-hours session in front of earnings, and then jumping more than 9% in after-hours action after reporting an earnings beat after the closing bell rang.Holding the market back more than any other name was Fastly (NYSE:FSLY). Although it rallied more than 2% after the closing bell rang, that move didn't even come close to offsetting the stock's 12.5% setback during the normal session … a move mostly prompted by profit-taking after an incredible runup since mid-August.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Buy for September As for names worth a look as trading prospects headed into the long weekend though, take a look at the stock charts of Mylan (NASDAQ:MYL), Home Depot (NYSE:HD) and Newell (NASDAQ:NWL). Here's what's most noteworthy, and how that may point to what lies ahead. Newell (NWL)Newell shares have been fighting a losing battle since the middle of 2017. And, technically speaking, it's still within the confines of a well-established downtrend.On the other hand, thanks to a slow turnaround effort that started to take shape just a few weeks ago, NWL stock is close to snapping its way out of the slump. Just know that Newell has been in this condition before, only to be up-ended before it took off. But, this time it is shaping up a little bit differently. * Click to EnlargeThe upper edge of the bearish trend is the convergence of the white 200-day moving average line, and the dashed blue line that connects all the key highs going back to the beginning of last year. * Underscoring the budding bullish effort thus far is the fact that the Chaikin line is now back above zero, suggesting there's a healthy amount of volume behind the current advance. * If the prospective breakout ends up taking shape, the most plausible upside target is the 38.2% Fibonacci retracement level of $28.85. A move to that mark still wouldn't be in a straight line though. Home Depot (HD)The past couple of weeks have been good ones for Home Depot, and things were particularly hot yesterday. Thursday's 2% pop carried shares above a near-term ceiling, to bring the two-week advance to 13%. The move, however, also stopped right at another, more established technical ceiling.That momentum is compelling to be sure, particularly given how it first took shape. But, the odds of there being any more upside left to dish out are pretty slim, given everything else evident on the chart. * 7 Mega-Cap Tech Stocks on a Rebound Now * Click to EnlargeThe rally appears to have been capped at the resistance level that aligns Thursday's high with the peaks made in September and January of last year. It's the upper of the two blue lines that frame the rising trading range marked on the weekly chart. * HD stock has also now punched through the upper boundary of a shorter-term trading range, marked by red dashed lines on both stock charts. This hints at a breakout, but the sheer scope of the advance thus far is unusually big. * Underscoring the above-average odds of a pullback from here is the fact that the weekly chart's RSI indicator is very near its overbought level. Mylan (MYL)Finally, Mylan has been routed since the beginning of 2018. In fact, it looked downright unsalvageable in May thanks to a hard-hitting selloff.In some ways though, that drubbing may have ultimately been the best thing for it. Although Mylan shares have yet to work their way back into a bullish mode -- and are still far from it -- the recent action suggests May's meltdown may have served as a capitulation. Better still, the proverbial lines in the sand are pretty clear. * Click to EnlargeThe pinnacle line in the sand is the falling resistance line that connects all the peaks going back to January of 2018, marked in red on the weekly chart. It's currently at $27, and falling fast. * Also note the gray 100-day moving average line is soon going to be tested as a technical ceiling. It has been a problem several times in the recent past, albeit not exactly. * It's small, but MYL stock has made a string of higher lows since May's low, plotted with a yellow line. It's the longest string of higher lows seen in well over year.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about him at his website jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 8 Worst Stocks to Buy Before the Trade Turmoil Cools Off * 7 'Strong Buy' Stocks to Beat Volatility * 7 Mega-Cap Tech Stocks on a Rebound Now The post 3 Big Stock Charts for Friday: Mylan, Newell and Home Depot appeared first on InvestorPlace.
Mylan stock popped Thursday after the Food and Drug Administration tentatively approved its generic version of Eli Lilly's chemotherapy, Alimta. Lilly stock also rose in afternoon action.
U.S. equities bounded higher on Monday as President Donald Trump hinted that talks with Chinese officials over trade were continuing -- something that Beijing denied. On the surface, it looks like another Trump "Sunday Night Special" started the week off on a positive note after the futures were down hard in overnight trading.In other words, it looks like Trump is playing fast and loose with the facts to keep stock prices higher. Which for millions of investors watching their 401(k) balances, is just fine. * 10 Companies Using AI to Grow With trade temporarily removed as an issue to be concerned about, at least for today, investors are instead focusing on some corporate M&A activity in the biotechnology space. Biotech stocks overall, as represented by the iShares Biotechnology ETF (IBB), are holding up fairly well amid recent market volatility. A rebound to test the early July highs seems in order.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnd these four stocks look ready to lead the way: Amgen (AMGN)Amgen (NASDAQ:AMGN) shares are testing their record highs near $205 after Bristol-Myers Squibb (NYSE:BMY) sold Celgene's (NASDAQ:CELG) Otezla psoriasis drug to the company for $13.4 billion in cash. All three of these stocks to buy are trading higher in response. The deal was done in response to an order by the Federal Trade Commission to secure BMY's acquisition of CELG as it already had a competitive anti-inflammatory psoriasis drug in its pipeline.The company will next report results on Oct. 29 after the close. Analysts are looking for earnings of $3.08 per share. When the company last reported on July 30, earnings of $3.97 per share beat estimates by 39 cents on a 3.1% decline in revenues. The company pays a 2.9% dividend yield. Bristol-Myers Squibb (BMY)BMY shares are testing above their 200-day moving average for the first time since the middle of 2018, rising out of a five-month consolidation range. Shares are benefiting from the sale of Celgene's Otezla drug to Amgen, satisfying regulatory requirements for its purchase of Celgene. The deal hinges on Celgene's pipeline of cancer-fighting drugs in development. * 7 "Boring" Stocks With Exciting Prospects The company is also being noticed for its dividend payout, which totals a 3.5% yield. BMY will next report results on Oct. 24 before the bell. Analysts are looking for earnings of $1.06 per share on revenues of $5.85 billion. When the company last reported on July 25, earnings of $1.18 beat estimates by 12 cents on a 10% rise in revenues. Celgene (CELG)Celgene's shares look ready to break out of a five-month consolidation range with a push up and over the $100-a-share level. As a reminder, the company's $74 billion buyout by Bristol-Myers Squibb works out to $50 in cash and one share of BMY, which is worth about $98 right now. This stock now basically trades as a derivative of BMY shares, as odds of the acquisition being approved move towards 100%.The company will next report results on Oct. 24. Analysts are looking for earnings of $2.70 per share on revenues of $4.39 billion. When the company last reported on July 30, earnings of $2.86 beat by 24 cents on a 15.4% rise in revenues. Mylan (MYL)Mylan (NASDAQ:MYL) shares look ready to rise off of a solid base of support near $19 that has been in play since late May. Back in July, the company agreed to combine with Pfizer's (NYSE:PFE) off-patent business, giving MYL's shareholders 43% of the combined company. Coverage of the stock was initiated back in June by Barclays analysts with an overweight rating.The company will next report results on Nov. 5 before the bell. Analysts are looking for earnings of $1.14 per share on revenues of $3 billion. When the company last reported on July 29, earnings of $1.03 per share beat estimates by eight cents on a 1.5% rise in revenues. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Companies Using AI to Grow * The 10 Biggest Winners From Second-Quarter Earnings * 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk The post 4 Biotech Stocks to Buy That Are on the Move appeared first on InvestorPlace.
News of Novo Nordisk suing Mylan is spreading as the two companies prepare for a legal battle.Source: joreks / Shutterstock.com The reason behind the upcoming legal battle has to do with Victoza. This is Novo Nordisk's (NYSE:NVO) drug for treating diabetes. Mylan (NASDAQ:MYL) is looking to market its own generic version of the drug, which is where the rub comes from.Novo Nordisk is seeking to block any efforts by Mylan to market its generic version of Victoza. Having a generic version of the drug available would eat into the revenue the company would make from selling its name brand version.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNovo Nordisk is also seeking to protect its products that still have patent protection. The patents surrounding Victoza will start expiring in July 2021 and the last one will reach its expiration date in March 2033, reports BioSpace.Novo Nordisk suing Mylan specifically has to do with this new drug from the latter being an alleged illegal generic of its own. The company is filing this lawsuit in response to an abbreviated new drug application filed by Mylan with the U.S. Food & Drug Administration. * 10 Marijuana Stocks That Could See 100% Gains, If Not More The lawsuit from Novo Nordisk against Mylan was filed on Monday. This had the company filing its lawsuit with the U.S. District Court for the District of Delaware. Lawsuits can be lengthy procedures, so it will likely be some time before we see the outcome of this one.NVO stock was up 1% and MYL stock was down slightly as of Thursday afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip As of this writing, William White did not hold a position in any of the aforementioned securities.The post Novo Nordisk Suing Mylan Over Generic Victoza Drug appeared first on InvestorPlace.
Teva Pharmaceutical Industries Ltd said on Tuesday its generic version of Mylan's EpiPen for young children will be available in most retail pharmacies at a price of $300 for a 2-pack. Israel-based Teva, the world's largest generic drugmaker, is already selling the product for adults, after getting U.S. approval for its copy of EpiPen in August following several years of delay. Mylan also produces a generic version of its own life-saving EpiPen allergy treatment, which like Teva's product is priced at about $300.